High-risk types of human papillomavirus (hrHPV) have been implicated in the vast majority of cases of high-grade cervical dysplasia and cervical carcinoma, 1 and hrHPV testing has emerged as a highly sensitive test for the presence of cervical neoplasia. 2 A wide variety of tests are currently available for the detection of hrHPV. Although the variety of available tests provides many options for laboratories using a hrHPV test, it is important that laboratories use analytically as well as clinically validated assays. 3 Unlike low-risk types of HPV, in which the HPV genome is typically maintained in a nonintegrated (episomal) form, hrHPV has the ability to integrate into the host genome, 4 ultimately leading to the overexpression of E6 and E7 viral genes. These genes may act to transform and immortalize cells via protein binding and inactivation of p53 and pRB tumor suppressor genes. [5] [6] [7] Although hrHPV is implicated in virtually all cases of cervical carcinoma, it most often manifests as a self-limited resolving infection, with approximately 70% of cases resolved after 1 year and 90% of cases resolved after 2 years. 8 Because the incidence of hrHPV is much higher than that of cervical neoplasia, testing for hrHPV has not been shown to be as cost-effective as a stand-alone primary screening test in the general population. 9 Rather, as concluded from data generated by the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (the ALTS trial), hrHPV testing has been established as a primary triage test for cervical cytology specimens with atypical squamous cells of undetermined significance (ASC-US) results. 10, 11 An additional indication for hrHPV testing that has emerged more recently is as primary screening for women aged >30 years who have had a normal Papanicolaou (Pap) test. 12, 13 This is because of the finding that women in this subgroup have a lower incidence of hrHPV infection and a higher incidence of cervical dysplasia or carcinoma when HPV is present compared with patients aged <30 years. 14, 15 The Qiagen Hybrid Capture II (HC II; Qiagen, Valencia, CA) test is the most commonly used test for hrHPV and, along with the Cervista hrHPV test (Hologic, Marlborough, MA), is 1 of 2 available testing methods approved by the US Food and Drug Administration (FDA). 16 Although the HC II has been approved when To the best of our knowledge, few studies to date have examined the subsequent cervical histology from patients whose cervical hrHPV tests have shown ''equivocal'' results. 19 In addition, to our knowledge only a few studies to date have examined the relation between the level of hrHPV found in cervical specimens and the incidence of cervical dysplasia detected on follow-up histology. 20, 21 Because the HC II is a qualitative as well as semiquantitative test, the RLU/CO value may be used as a surrogate for the hrHPV level (ie, copy number). In this study, we further examined the relation between the hrHPV level and the presence of dysplasia on follow-up histology.
MATERIALS AND METHODS

Patient Sample Selection
The study examined all hrHPV tests over an 18-month period in our laboratory, corresponding to a total volume of 5297 hrHPV tests. During this time period, 72,056
liquid-based Pap tests were completed at the Massachusetts General Hospital, of which >97% represented SurePath specimens. hrHPV tests that were initially reported to be within the equivocal range were selected for review of subsequent hrHPV test results, including corresponding cytopathologic and histopathologic results over a 2-year follow-up period. A subset of equivocal hrHPV tests corresponding to Pap tests demonstrating ASC-US cytology were reviewed and compared with a numerically matched cohort of patients who had ASC-US cytology and an associated unequivocal positive hrHPV test. This latter group was selected based on consecutive cases tested for hrHPV during the study time period (n ¼ 148 patients).
High-Risk HPV Assay
The HC II hrHPV Assay is an in vitro nucleic acid hybridization assay that detects 13 high-risk types of HPV (specifically, types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68). The assay was performed as reported previously. 19 Briefly, an aliquot of residual Pap test preservative medium from either a SurePath or ThinPrep Pap test was incubated with a probe cocktail containing hrHPV-specific RNA molecules, performed on 96-well plates. After hybridization, antibodies conjugated with alkaline phosphatase and specific for RNA:DNA hybrids were added, followed by a chemiluminescent substrate. Results were quantified via luminometer. Positive and negative controls were comprised of HPV-16 DNA and non-hrHPV DNA, respectively. SurePath samples were prepared for the HC II assay as previously described. 17 ThinPrep samples were prepared for the HC II assay as per the manufacturer's FDA-approved protocol. Results were reported as specified for ThinPrep sample labeling, and as specified earlier.
Cytopathologic and Histopathologic Preparation and Staining
Cytopathologic and histopathologic results were based on a review of cytology and histology reports generated during the 22-month time frame of the study and extended to a period of up to 2 years after the index Pap test on which the hrHPV test was based. Histopathological results of cervical intraepithelial neoplasia (CIN) type II (CIN II) or CIN III were re-reviewed and confirmed by 2 pathologists for this study.
RESULTS
Cytologic and Histologic Results of All Equivocal Tests
The total cohort of patients whose hrHPV tests demonstrated ''equivocal'' results was 209 (4%) of 5297 total tests over the 18-month period of study. These tests were found to be positive for hrHPV at the time of retesting in 202 of 209 (97%) cases ( 
Chemiluminescence Intensity of hrHPV Tests Based on Histologic Diagnosis
The chemiluminescence intensity of unequivocal positive hrHPV tests from patients found to have ASC-US cytology on a corresponding Pap test was correlated with the follow-up histologic results (Fig. 4) 
Histologic Results Based on hrHPV Test Chemiluminescence Intensity
Follow-up histology corresponding to patients found to have ASC-US on cytology and a concomitant nonequivocal positive hrHPV test were correlated with chemiluminescence intensity. The median hrHPV chemiluminescence intensity of 148 cases was 61.54 RLU/CO. Figure 5 shows the resulting follow-up histology of patients corresponding to those whose RLU/CO value was below the median (range, 2.74-57.71 RLU/CO) or above the median (range, 65.36-2361.88 RLU/CO). The follow-up histology of samples corresponding to hrHPV tests with chemiluminescence intensity that was below the median was no follow-up in 29.7% of samples, negative for dysplasia in 37.8% of samples, CIN I in 16.2% of samples, or CIN II/III in 16.2% of samples. The followup histology of samples corresponding to hrHPV tests with chemiluminescence intensity that was above the median was no follow-up in 37.8% of samples, negative for displasia in 33.8% of samples, CIN I in 14.9% of samples, or CIN II/III in 13.5% of samples. Figure 6 shows the same 2 groups expressed as a percentage of the biopsied cohort. The available follow-up histology of samples corresponding to hrHPV tests with RLU/CO values >1000 (n ¼ 19 samples) were NILM in 7 samples (37%), CIN I in 7 samples (37%), or CIN II/III in 5 samples (26%). Figure 7 shows the histologic follow-up when the groups were divided into 4 equal subsets based on chemiluminescence intensity.
DISCUSSION
The main objectives of the current study were 1) to provide 2-year histologic follow-up for the assessment of pathology associated with equivocal hrHPV results; 2) compare follow-up dysplasia rates after ASC-US Pap test results and equivocal hrHPV tests with dysplasia rates in a similar group of patients with unequivocal positive hrHPV results; and 3) correlate the chemiluminescent intensity of a positive HC II hrHPV test with the risk of cervical dysplasia on a follow-up cervical biopsy. We previously reported a 4% initial equivocal hrHPV test rate and the subsequent conversion of 97.4% of those tests to positive at the time of retesting. 19 This number is higher than that presented in the manufacturer's packaging insert when examining the final hrHPV positive rate after testing equivocal samples. The manufacturer found a subsequent final positive rate of 177 of 219 samples (81%) when using PreservCyt as the specimen medium and 127 of 140 samples (91%) when using STM as the specimen medium. On the basis of these data alone, and not followup histology, the manufacturer recommends repeat testing when specimens are preserved in PreservCyt but does not recommend retesting when specimens are preserved in STM due to the higher reproducibility of the latter.
Given that our retesting results demonstrated higher reproducibility (ie, 97%) than either of the manufacturer's tests, this lends strong support to the conclusion that these tests do not need to be repeated. The current study is comprised of samples preserved predominantly in SurePath media, which has been shown to exhibit reproducible results with the HC II hrHPV assay at the time of retesting. 17, 22 SurePath is the predominant liquid-based media (>97%) used for Pap tests at the reference institution, and therefore the preponderance of SurePath media in the current study reflects the mix of Pap tests at the reference institution and not inherent qualities of either SurePath or ThinPrep media. The best rationale for treating these ''equivocal'' tests as true-positive results can be found in examining the follow-up histologic results. Thus, in addition to retesting, we explored the 2-year histologic follow-up of cervical biopsies associated with the ''equivocal'' tests to definitively determine whether these tests differ with regard to unequivocal positive hrHPV tests. Because dysplasia rates may vary depending on the patient population being served, 10 we compared follow-up histology from ''equivocal'' hrHPV tests with unequivocal positive hrHPV tests in our laboratory. In our laboratory, the 2-year total risk of dysplasia (CIN I/II/III) after an ASC-US Pap test was 43.5% or 45.9% of the biopsied cohort for ''equivocal'' or positive hrHPV tests, respectively; and the 2-year risk of high-grade dysplasia (CIN II/III) after an ASC-US Pap test was 16.5% or 22.4% of the biopsied cohort for ''equivocal'' or positive hrHPV tests, respectively. As a comparison, the ALTS trial reported a 2-year follow-up rate of high-grade dysplasia of 26% in their biopsied cohort, which was an average of the rates found among the 4 participating institutions. 10, 11 Thus, on the basis of the outcome of either hrHPV retesting or subsequent histologic biopsy, data from the current study suggest that hrHPV tests with an initial value >1.0 RLU/CO be treated as an unequivocal positive hrHPV test, and that repeat testing of these samples is unnecessary. To our knowledge, few studies to date have examined the significance of ''equivocal'' hrHPV results obtained from HC II. 23 To our knowledge, the current study is the first to provide a broad picture of the predictive value of chemiluminescence intensity derived from the HC II hrHPV test from the lowest, most equivocally positive specimens to the highest values generally obtained in laboratories. Although to the best of our knowledge no other single institution has examined this on as broad a scale, several other studies have examined the relation between hrHPV viral load and subsequently detected cervical dysplasia. [24] [25] [26] [27] [28] [29] The recently published series from Sargent et al 29 reported a reduced rate of high-grade dysplasia after an hrHPV test, with an RLU/CO value of between 1 and 2 (ie, 9.2% vs 17.9% for an RLU/CO value 2.0), although their methodology differs considerably from that of the current present study (eg, combining ''borderline'' and ''mild'' cytology). Nevertheless, the indicated rate of 9.2% represents a nearly 5-fold risk compared with that associated with negative hrHPV tests in the study by Sargent et al. 29 Using polymerase chain reaction-based hrHPV detection, an increase in the viral load of carcinogenic subtypes demonstrates a positive correlation with cervical abnormalities in the general population (ie, when all Pap diagnoses are included), 26 and the association between type-specific HPV-16 viral load with CIN III or cancer indicates a positive correlation in patients with negative cervical cytology, but not those with ASC-US cytology. 24 When HC II was used to detect hrHPV subtypes, no association was noted between increasing viral load and the risk of CIN III or cancer, 27 although a modest positive correlation was observed for CIN I. 21 Further analysis of specimens gathered from the ALTS trial demonstrated that higher hrHPV viral load is associated with a greater prevalence of multiple hrHPV subtypes and exfoliated ASC-US/LSIL cells, but not exfoliated ASC-H or HSIL cells. 28 Thus, these studies suggest that using hrHPV viral load to predict severe dysplasia in a clinically relevant setting is not possible. Data from the current study lend further support to this hypothesis, because we examined a highly clinically relevant population (ie, a population with hrHPV positivity and ASC-US cytology) and found no correlation with viral load and the presence or severity of subsequently detected dysplasia. We chose to divide patients evenly into either halves or quartiles based on HC II chemiluminescence intensity and found no significant difference between either low-grade or high-grade dysplasia. Other methods of segregating samples based on viral load (eg, an RLU/CO value >1000) also failed to demonstrate a correlation among the current study data, although our dataset for specimens with a RLU/CO value >1000 was small because such specimens comprise a small subset of positive hrHPV tests (ie, 6% in the current series). In addition, this subset has been examined exclusively in another study and has been shown to be associated with a modest increase of low-grade (CIN I) lesions, but not high-grade lesions (ie, CIN II or above). 21 Presumably, low-grade dysplasias may demonstrate a higher viral load given that these infections are productive, nonintegrated infections, and active viral replication is taking place. The results of the current study cannot fully address this theory because we were unable to ascertain the presence of absence of CIN I in those cases in which a CIN II or CIN III lesion was detected; thus, CIN I lesions may be found in any or all cases demonstrating CIN II or CIN III. The histologic results of each biopsy were reported based on the highest grade of dysplasia present as opposed to all grades of dysplasia that were present. In addition, colposcopically directed biopsies are aimed at sampling the highest grades of dysplasia versus detecting all areas of low-grade dysplasia that may be present. Thus, the complex and most likely multiple opposing sets of biologic principals affecting the association between viral load and dysplasia are difficult to dissect in the current study. However, the relevant association between viral load and high-grade dysplasia in clinically relevant samples is not difficult to dissect: the results of the current study strongly refute the belief that viral load can predict the degree or presence of high-grade dysplasia in histologic cervical samples after an abnormal Pap test.
